Press release
GM2 Gangliosidosis Market Outlook, Trends, Therapies and Growth Forecast
GM2 Gangliosidosis
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70913
Although rare, GM2 gangliosidosis represents a critical unmet need in rare disease therapeutics, as no curative treatment currently exists. Standard care is largely supportive, focusing on managing seizures, mobility impairment, and respiratory complications. However, gene therapy, enzyme replacement therapy (ERT), and substrate reduction therapy (SRT) are revolutionizing research in this space.
By 2034, the GM2 Gangliosidosis Market is expected to reach USD 2.3 billion, up from USD 710 million in 2024, growing at a CAGR of 12.3%.
Market Overview
• Market Size 2024: USD 710 million
• Forecast 2034: USD 2.3 billion
• CAGR (2024-2034): ~12.3%
Key Growth Drivers:
• Rising global awareness and newborn screening programs for rare genetic diseases.
• Expanding pipeline of gene therapies (AAV-based vectors).
• Supportive regulatory frameworks such as orphan drug designations.
• Growth of patient advocacy groups accelerating funding and clinical trials.
Challenges:
• High R&D costs for ultra-rare disease drugs.
• Complex clinical trial designs with small patient populations.
• Limited treatment access in developing regions.
Leading Players:
Axovant Gene Therapies (Sio Gene Therapies), Passage Bio, Polaryx Therapeutics, Sanofi Genzyme, Amicus Therapeutics, Takeda, Sarepta Therapeutics, Orchard Therapeutics, Taysha Gene Therapies, and BioMarin.
Segmentation Analysis
By Product
• Gene Therapy (AAV-based, Lentiviral-based)
• Enzyme Replacement Therapy (ERT)
• Substrate Reduction Therapy (SRT)
• Small-Molecule Therapy
• Supportive Care Drugs
By Platform
• In Vivo Gene Therapy
• Ex Vivo Gene Therapy
• Enzyme Infusion Platforms
• Oral Substrate Reduction
By Technology
• Viral Vector Engineering
• CRISPR & Genome Editing
• Biomarker-Based Diagnostics
• Next-Generation Sequencing (NGS)
By End Use
• Hospitals & Specialty Clinics
• Research & Academic Institutes
• Diagnostic Laboratories
• Biopharmaceutical Companies
By Application
• Tay-Sachs Disease
• Sandhoff Disease
• GM2 Activator Deficiency
Segmentation Summary:
Tay-Sachs disease dominates the market due to higher prevalence, but Sandhoff disease research is expanding rapidly. Gene therapies are set to become the most transformative product segment by 2034.
Explore Full Report here: https://exactitudeconsultancy.com/reports/70913/gm2-gangliosidosis-market
Regional Analysis
North America
• Largest market share (~44% in 2024).
• Strong presence of clinical trials and FDA orphan drug approvals.
• Patient advocacy groups (e.g., NTSAD) accelerating awareness.
Europe
• Significant research funding and EMA support.
• Germany, UK, and France leading in newborn screening and rare disease trials.
Asia-Pacific
• Fastest-growing market (CAGR ~14%).
• Rising genetic testing adoption in Japan, China, and South Korea.
• Expanding biotech investments in rare diseases.
Middle East & Africa
• Limited awareness and access, but growing medical genetics initiatives.
• GCC countries improving rare disease infrastructure.
Latin America
• Brazil and Mexico increasing investment in rare disease diagnostics.
• Early-stage adoption of gene therapies expected post-2030.
Regional Summary:
North America and Europe dominate current revenues, while Asia-Pacific is set for exponential growth due to genetic screening, rising research collaborations, and biotechnology investments.
Market Dynamics
Growth Drivers
• Expanding orphan drug designations and regulatory fast-tracks.
• Advances in viral vector engineering and CRISPR-based therapies.
• Increased global funding for rare disease research.
• Strong support from patient advocacy networks.
Key Challenges
• Pricing pressures for ultra-rare disease treatments.
• Limited patient recruitment for clinical trials.
• Manufacturing and supply chain challenges in gene therapy.
Latest Trends
• Shift towards one-time curative therapies.
• Partnerships between biotech firms and academic institutions.
• AI-driven genetic diagnostics enabling earlier detection.
• Strong focus on newborn screening initiatives.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70913
Competitor Analysis
Major Players:
1. Sio Gene Therapies (Axovant)
2. Passage Bio
3. Polaryx Therapeutics
4. Amicus Therapeutics
5. Sanofi Genzyme
6. Takeda Pharmaceutical
7. Sarepta Therapeutics
8. Orchard Therapeutics
9. Taysha Gene Therapies
10. BioMarin
Competitive Summary:
The market is highly innovation-driven, with players investing in AAV-based gene therapies and substrate reduction drugs. Partnerships with academic institutions and patient groups are accelerating trial enrollment and awareness. Companies with successful gene therapy approvals will dominate by 2034.
Conclusion
The GM2 Gangliosidosis Market is entering a transformative era, driven by breakthroughs in gene therapy, enzyme replacement, and genome editing. With strong regulatory support and patient advocacy momentum, therapies once considered science fiction are becoming a reality.
Key Takeaways:
• Market to expand from USD 710 million in 2024 to USD 2.3 billion by 2034, CAGR 12.3%.
• Tay-Sachs disease leads, but Sandhoff disease research is accelerating.
• North America dominates, while Asia-Pacific is the fastest-growing region.
• Innovation in gene therapy, CRISPR, and newborn screening will define the next decade.
By 2034, GM2 gangliosidosis treatment is expected to shift from supportive care to curative interventions, significantly improving patient survival and quality of life.
This report is also available in the following languages : Japanese (GM2ガングリオシドーシス市場), Korean (GM2 강글리오사이드증 시장), Chinese (GM2神经节苷脂沉积症市场), French (Marché de la gangliosidose à GM2), German (GM2-Gangliosidose-Markt), and Italian (Mercato della gangliosidosi GM2), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/70913/gm2-gangliosidosis-market#request-a-sample
Our More Reports:
Myelodysplastic Syndrome Market
https://exactitudeconsultancy.com/reports/71289/myelodysplastic-syndrome-market
Myelofibrosis Market
https://exactitudeconsultancy.com/reports/71290/myelofibrosis-market
Paroxysmal Nocturnal Hemoglobinuria Market
https://exactitudeconsultancy.com/reports/71291/paroxysmal-nocturnal-hemoglobinuria-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GM2 Gangliosidosis Market Outlook, Trends, Therapies and Growth Forecast here
News-ID: 4147892 • Views: …
More Releases from Exactitude Consultancy
Parkinson's Disease Psychosis (PDP) Market reaching approximately USD 3.7 billio …
Parkinson's disease (PD) is a chronic neurodegenerative disorder marked by tremors, rigidity, and movement difficulties. Beyond motor symptoms, many patients also develop Parkinson's disease psychosis (PDP), a non-motor complication characterized by hallucinations and delusions. PDP affects nearly half of advanced PD patients, contributing significantly to morbidity, caregiver burden, and long-term care requirements.
Historically, PDP management has been challenging because many antipsychotics worsen motor symptoms by interfering with dopamine pathways. However, with…
Parkinson's Disease Levodopa-Induced Dyskinesia (LID) Market New Product Develop …
Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting movement, characterized by tremors, stiffness, and impaired coordination. Levodopa remains the gold standard for managing motor symptoms, but long-term use often results in levodopa-induced dyskinesia (LID) - a debilitating complication involving involuntary, erratic movements.
As patients live longer due to improved disease management, the incidence of LID continues to rise. The burden of dyskinesia not only reduces quality of life but also…
Peripheral Nerve Injuries Market reaching approximately USD 4.9 billion by 2034
Peripheral nerve injuries (PNIs) occur when nerves outside the brain and spinal cord are damaged, often leading to loss of motor function, sensory deficits, or chronic neuropathic pain. These injuries are commonly caused by trauma, surgery, repetitive stress, or medical conditions such as diabetes. Depending on severity, PNIs may involve partial or complete disruption of nerve fibers, significantly affecting patient quality of life.
The burden of PNIs is rising globally due…
Post-Traumatic Stress Disorder (PTSD) Market reaching approximately USD 13.4 bil …
Post-traumatic stress disorder (PTSD) is a psychiatric condition that develops after exposure to traumatic events such as combat, natural disasters, serious accidents, or violence. It manifests through symptoms like flashbacks, nightmares, heightened anxiety, and emotional numbness, often impairing daily functioning and quality of life. While once underdiagnosed and stigmatized, PTSD is increasingly recognized as a major public health concern worldwide.
The growing prevalence of PTSD among military veterans, first responders, survivors…
More Releases for GM2
Global GM2 Gangliosidosis Clinical Trials 2025: Drug Pipeline, Regulatory Approv …
DelveInsight's "GM2 Gangliosidosis - Pipeline Insight, 2025" delivers an in-depth evaluation of the global research and development landscape, profiling both clinical and preclinical drug candidates with varied mechanisms of action. The report explores key advancements including AAV-based gene therapies focused on the central nervous system, innovations in delivery technologies, and novel approaches aimed at improving long-term safety and efficacy. It also examines shifting regulatory frameworks, biomarker-guided clinical trial designs, and…
GM2 Gangliosidosis Market Set to Advance Through 2034, Fueled by Gene Therapy In …
GM2 Gangliosidosis refers to a group of rare, inherited lysosomal storage disorders-including Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency-caused by mutations that impair the breakdown of GM2 gangliosides in nerve cells. These disorders are characterized by progressive neurodegeneration, muscle weakness, motor impairment, seizures, and early mortality, especially in infantile-onset forms. The most common types, Tay-Sachs and Sandhoff disease, result from mutations in the HEXA and HEXB genes, respectively.
DelveInsight's report,…
GM2 Gangliosidosis Pipeline Overview: 8+ Innovative Therapies Driving Hope in Ra …
The therapeutic landscape for GM2 gangliosidosis-an ultra-rare, inherited lysosomal storage disorder encompassing Tay-Sachs and Sandhoff diseases-is witnessing growing innovation, with the pipeline evolving toward more disease-modifying and potentially curative therapies. GM2 gangliosidosis is caused by mutations affecting β-hexosaminidase A and/or B enzymes, resulting in the toxic accumulation of GM2 gangliosides in neurons, which leads to progressive neurodegeneration. Despite the severity of this disease, current management remains largely supportive, highlighting an…
GM2 Gangliosidosis Market is Predicted to Exhibit Remarkable Growth During the F …
DelveInsight's "GM2 Gangliosidosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the GM2 Gangliosidosis, historical and forecasted epidemiology as well as the GM2 Gangliosidosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the GM2 Gangliosidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GM2 Gangliosidosis Market Forecast
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
GM2 Gangliosidosis Pipeline Analysis (2023) Covering Clinical Trials, Emerging T …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 8+ pipeline drugs in the GM2 Gangliosidosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"GM2 Gangliosidosis Pipeline Insight, 2023" report…
GM2 Gangliosidosis Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging …
GM2 Gangliosidosis pipeline constitutes 8+ key companies continuously working towards developing 8+ GM2 Gangliosidosis treatment therapies, analyzes DelveInsight
GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay-Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic…
